Charles Schwab Investment Management Inc. Boosts Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Charles Schwab Investment Management Inc. grew its position in UroGen Pharma Ltd. (NASDAQ:URGN) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,517 shares of the company’s stock after buying an additional 3,024 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.40% of UroGen Pharma worth $996,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. RTW Investments LP raised its position in UroGen Pharma by 6.5% during the third quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock worth $48,099,000 after acquiring an additional 230,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of UroGen Pharma by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company’s stock valued at $17,032,000 after acquiring an additional 21,072 shares during the last quarter. State Street Corp boosted its stake in shares of UroGen Pharma by 5.9% during the 3rd quarter. State Street Corp now owns 769,583 shares of the company’s stock worth $9,774,000 after purchasing an additional 42,907 shares during the last quarter. Geode Capital Management LLC raised its position in shares of UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after buying an additional 34,248 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of UroGen Pharma by 26.6% during the third quarter. Parkman Healthcare Partners LLC now owns 347,541 shares of the company’s stock valued at $4,414,000 after buying an additional 73,076 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Buying and Selling

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

UroGen Pharma Stock Performance

UroGen Pharma stock opened at $11.20 on Monday. The stock’s 50-day moving average is $10.66 and its 200-day moving average is $11.49. The company has a market cap of $516.25 million, a price-to-earnings ratio of -3.56 and a beta of 1.12. UroGen Pharma Ltd. has a 12 month low of $9.03 and a 12 month high of $20.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. Equities analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price for the company. HC Wainwright cut their price objective on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a report on Monday, March 10th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $38.20.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.